These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 35201613)
21. Efficiency gains in tracer identification for nuclear imaging: can in vivo LC-MS/MS evaluation of small molecules screen for successful PET tracers? Joshi EM; Need A; Schaus J; Chen Z; Benesh D; Mitch C; Morton S; Raub TJ; Phebus L; Barth V ACS Chem Neurosci; 2014 Dec; 5(12):1154-63. PubMed ID: 25247893 [TBL] [Abstract][Full Text] [Related]
22. PET reporter systems for the brain. Nerella SG; Michaelides M; Minamimoto T; Innis RB; Pike VW; Eldridge MAG Trends Neurosci; 2023 Nov; 46(11):941-952. PubMed ID: 37734962 [TBL] [Abstract][Full Text] [Related]
23. [Clinical evaluation of CNS drugs with PET]. Takano A Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):61-5. PubMed ID: 19562943 [TBL] [Abstract][Full Text] [Related]
24. Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening. Xiao H; Sun M; Zhao R; Hong H; Zhang A; Zhang S; Liu F; Zhang Y; Liu Y; Zhu L; Kung HF; Qiao J J Pharm Biomed Anal; 2018 May; 154():48-56. PubMed ID: 29533858 [TBL] [Abstract][Full Text] [Related]
25. Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. Borroni E; Zhou Y; Ostrowitzki S; Alberati D; Kumar A; Hainzl D; Hartung T; Hilton J; Dannals RF; Wong DF Neuroimage; 2013 Jul; 75():291-300. PubMed ID: 22178811 [TBL] [Abstract][Full Text] [Related]
26. In vitro binding affinity vs. in vivo site occupancy: A PET study of four diastereomers of dihydrotetrabenazine (DTBZ) in monkey brain. Kilbourn MR; Cole EL; Scott PJH Nucl Med Biol; 2021 Jan; 92():38-42. PubMed ID: 32122751 [TBL] [Abstract][Full Text] [Related]
27. Imaging Kappa Opioid Receptors in the Living Brain with Positron Emission Tomography. Placzek MS Handb Exp Pharmacol; 2022; 271():547-577. PubMed ID: 34363128 [TBL] [Abstract][Full Text] [Related]
28. Non-invasive imaging in experimental medicine for drug development. Matthews PM; Rabiner I; Gunn R Curr Opin Pharmacol; 2011 Oct; 11(5):501-7. PubMed ID: 21570913 [TBL] [Abstract][Full Text] [Related]
30. Development and Evaluation of Two Potential 5-HT Tampio L'Estrade E; Xiong M; Shalgunov V; Edgar FG; Volk B; Baerentzen SL; Palner M; Erlandsson M; Ohlsson T; Knudsen GM; Herth MM ACS Chem Neurosci; 2019 Sep; 10(9):3961-3968. PubMed ID: 30973705 [TBL] [Abstract][Full Text] [Related]
31. PET Imaging of nicotinic acetylcholine receptors in baboons with 18F-AZAN, a radioligand with improved brain kinetics. Kuwabara H; Wong DF; Gao Y; Valentine H; Holt DP; Ravert HT; Dannals RF; Horti AG J Nucl Med; 2012 Jan; 53(1):121-9. PubMed ID: 22173841 [TBL] [Abstract][Full Text] [Related]
32. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. Wang Y; Klunk WE; Debnath ML; Huang GF; Holt DP; Shao L; Mathis CA J Mol Neurosci; 2004; 24(1):55-62. PubMed ID: 15314250 [TBL] [Abstract][Full Text] [Related]
33. Development of PET and SPECT probes for glutamate receptors. Fuchigami T; Nakayama M; Yoshida S ScientificWorldJournal; 2015; 2015():716514. PubMed ID: 25874256 [TBL] [Abstract][Full Text] [Related]
34. In vivo imaging of the metabotropic glutamate receptor 1 (mGluR1) with positron emission tomography: recent advance and perspective. Li S; Huang Y Curr Med Chem; 2014; 21(1):113-23. PubMed ID: 23992339 [TBL] [Abstract][Full Text] [Related]
35. Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development. Hou L; Rong J; Haider A; Ogasawara D; Varlow C; Schafroth MA; Mu L; Gan J; Xu H; Fowler CJ; Zhang MR; Vasdev N; Ametamey S; Cravatt BF; Wang L; Liang SH J Med Chem; 2021 Jan; 64(1):123-149. PubMed ID: 33379862 [TBL] [Abstract][Full Text] [Related]
36. A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). Huang Y; Hwang DR; Bae SA; Sudo Y; Guo N; Zhu Z; Narendran R; Laruelle M Nucl Med Biol; 2004 Jul; 31(5):543-56. PubMed ID: 15219271 [TBL] [Abstract][Full Text] [Related]
37. Molecular imaging PET and SPECT approaches for improving productivity of antipsychotic drug discovery and development. Catafau AM; Bullich S Curr Med Chem; 2013; 20(3):378-88. PubMed ID: 23157630 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242. Naganawa M; Jacobsen LK; Zheng MQ; Lin SF; Banerjee A; Byon W; Weinzimmer D; Tomasi G; Nabulsi N; Grimwood S; Badura LL; Carson RE; McCarthy TJ; Huang Y Neuroimage; 2014 Oct; 99():69-79. PubMed ID: 24844744 [TBL] [Abstract][Full Text] [Related]
39. What We Observe In Vivo Is Not Always What We See In Vitro: Development and Validation of 11C-JNJ-42491293, A Novel Radioligand for mGluR2. Leurquin-Sterk G; Celen S; Van Laere K; Koole M; Bormans G; Langlois X; Van Hecken A; Te Riele P; Alcázar J; Verbruggen A; de Hoon J; Andrés JI; Schmidt ME J Nucl Med; 2017 Jan; 58(1):110-116. PubMed ID: 27469358 [TBL] [Abstract][Full Text] [Related]